Kura Oncology Inc., of San Diego, said it priced an underwritten public offering of 7.7 million shares of its common stock at $6.50 each. The company has also granted the underwriters a 30-day option to purchase up to an additional 1.15 million shares of its common stock. The gross proceeds from the offering, excluding any exercise by the underwriters to purchase additional shares, are expected to be approximately $50.1 million.